GlaxoSmithKline's ($GSK) job-chopping ax has struck Hamilton, MT, where 27 vaccine researchers will pack up this year. The pharma giant plans to centralize its R&D efforts in one location, but where that will be hasn't yet been decided, company spokeswoman Melinda Stubbee told local paper Missoulian. Glaxo's vaccines unit is set for more changes later in 2015, too, as the company prepares to fold in the bulk of Novartis' ($NVS) vaccines unit--headed its way after their April 2014 multi-billion-dollar asset swap. More